Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effect of Eltrombopag on the Expression of Platelet Collagen Receptor Glycoprotein VI (GPVI) in Pediatric Patients With Chronic and Persistent Immune Thrombocytopenia.

NCT03412188 is registered in ClinicalTrials.gov with Nayera Hazaa Elsherif as lead sponsor.

NCT NCT03412188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effect of Eltrombopag on the Expression of Platelet Collagen Receptor Glycoprotein VI (GPVI) in Pediatric Patients With Chronic and Persistent Immune Thrombocytopenia.
Lead sponsor
Nayera Hazaa Elsherif
Phase
Not applicable
Overall status
Completed
Start date
August 1, 2018
Completion date
September 1, 2021
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura